A call for transplant stewardship: The need for expanded evidence‐based evaluation of induction and biologic‐based cost‐saving strategies in kidney transplantation and beyond
dc.contributor.author | Jorgenson, Margaret R. | |
dc.contributor.author | Descourouez, Jillian L. | |
dc.contributor.author | Brady, Bethany L. | |
dc.contributor.author | Chandran, Mary M. | |
dc.contributor.author | Do, Vincent | |
dc.contributor.author | Kim, Miae | |
dc.contributor.author | Laub, Melissa R. | |
dc.contributor.author | Lichvar, Alicia | |
dc.contributor.author | Park, Jeong M. | |
dc.contributor.author | Szczepanik, Amanda | |
dc.contributor.author | Alloway, Rita R. | |
dc.date.accessioned | 2021-11-02T00:44:50Z | |
dc.date.available | 2022-10-01 20:44:49 | en |
dc.date.available | 2021-11-02T00:44:50Z | |
dc.date.issued | 2021-09 | |
dc.identifier.citation | Jorgenson, Margaret R.; Descourouez, Jillian L.; Brady, Bethany L.; Chandran, Mary M.; Do, Vincent; Kim, Miae; Laub, Melissa R.; Lichvar, Alicia; Park, Jeong M.; Szczepanik, Amanda; Alloway, Rita R. (2021). "A call for transplant stewardship: The need for expanded evidence‐based evaluation of induction and biologic‐based cost‐saving strategies in kidney transplantation and beyond." Clinical Transplantation 35(9): n/a-n/a. | |
dc.identifier.issn | 0902-0063 | |
dc.identifier.issn | 1399-0012 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/170795 | |
dc.description.abstract | Rising expenditures threaten healthcare sustainability. While transplant programs are typically considered profitable, transplant medications are expensive and frequently targeted for cost savings. This review aims to summarize available literature supporting cost‐containment strategies used in solid organ transplant. Despite widespread use of these tactics, we found the available evidence to be fairly low quality. Strategies mainly focus on induction, particularly rabbit antithymocyte globulin (rATG), given its significant cost and the lack of consensus surrounding dosing. While there is higher‐quality evidence for high single‐dose rATG, and dose‐rounding protocols to reduce waste are likely low risk, more aggressive strategies, such as dosing rATG by CD3+ target‐attainment or on ideal‐body‐weight, have less robust support and did not always attain similar efficacy outcomes. Extrapolation of induction dosing strategies to rejection treatment is not supported by any currently available literature. Cost‐saving strategies for supportive therapies, such as IVIG and rituximab also have minimal literature support. Deferral of high‐cost agents to the outpatient arena is associated with minimal risk and increases reimbursement, although may increase complexity and cost‐burden for patients and infusion centers. The available evidence highlights the need for evaluation of unique patient‐specific clinical scenarios and optimization of therapies, rather than simple blanket application of cost‐saving initiatives in the transplant population. | |
dc.publisher | Novartis Pharmaceuticals Corporation | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | risk assessment/risk stratification | |
dc.subject.other | risk assessment/risk stratification | |
dc.subject.other | economics | |
dc.subject.other | immunosuppressive regimens | |
dc.subject.other | economics | |
dc.subject.other | immunosuppressive regimens | |
dc.subject.other | risk assessment/risk stratification | |
dc.subject.other | economics | |
dc.subject.other | immunosuppressive regimens | |
dc.subject.other | risk assessment/risk stratification | |
dc.subject.other | economics | |
dc.subject.other | immunosuppressive regimens | |
dc.title | A call for transplant stewardship: The need for expanded evidence‐based evaluation of induction and biologic‐based cost‐saving strategies in kidney transplantation and beyond | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Medicine (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/170795/1/ctr14372_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/170795/2/ctr14372.pdf | |
dc.identifier.doi | 10.1111/ctr.14372 | |
dc.identifier.source | Clinical Transplantation | |
dc.identifier.citedreference | Hirsch HH, Randhawa PS. BK polyomavirus in solid organ transplantation‐Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33 ( 9 ): e13528. | |
dc.identifier.citedreference | Hardinger K, Rasu R, Skelton R, et al. Thymoglobulin induction dosing strategies in a low‐risk kidney transplant population: three or four days? J Transpl. 2010; 2010: 1 ‐ 8. | |
dc.identifier.citedreference | Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single‐dose versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation: An interim report. Transplantation. 2008; 85: 1391 ‐ 1399. | |
dc.identifier.citedreference | Stevens RB, Foster KW, Miles CD, et al. A randomized 2x2 factorial trial, part 1: Single‐dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation. 2015; 99: 197 ‐ 209. | |
dc.identifier.citedreference | Stevens RB, Wrenshall LE, Miles CD, et al. A double‐blind, double‐dummy, flexible‐design randomized multicenter trial: early safety of single‐ versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation. Am J Transplant. 2016; 16 ( 6 ): 1858 ‐ 1867. https://doi.org/10.1111/ajt.13659 | |
dc.identifier.citedreference | Nafar M, Dalili N, Poor‐Reza‐Gholi F, et al. The appropriate dose of thymoglobulin induction therapy in kidney transplantation. Clin Transplant. 2017; 31 ( e12977 ): 1 ‐ 8. | |
dc.identifier.citedreference | Gaber AO, Firt MR, Tesi RJ, et al. Results of the double‐blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998; 66: 29 ‐ 37. | |
dc.identifier.citedreference | Wiland AM, Fink JC, Philosophe B, et al. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc. 2001; 33: 1910. | |
dc.identifier.citedreference | Marvin MR, Droogan C, Sawinski D, Cohen DJ, Hardy MA. Administration of rabbit antithymocyte globulin (Thymoglobulin) in ambulatory renal‐transplant patients. Transplantation. 2003; 75: 488 ‐ 489. | |
dc.identifier.citedreference | Erickson AL, Roberts K, Malek SK, Chandraker AK, Tullius SG, Gabardi S. Analysis of infusion‐site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab. Transpl Int. 2010; 23: 636 ‐ 640. | |
dc.identifier.citedreference | McGillicuddy JW, Taber DJ, Pilch NA, et al. Clinical economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation. Prog Transplant. 2013; 23: 33 ‐ 38. | |
dc.identifier.citedreference | Millennium and ILEX Partners, LP. Campath (ALEMTUZUMAB). Cambridge, MA: 2001. | |
dc.identifier.citedreference | Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone‐free maintenance immunotherapy in simultaneous pancreas‐kidney transplantation comparison with rabbit antithymocyte globulin induction – long term results. Am J Transplant. 2006; 6 ( 2 ): 331 ‐ 339. | |
dc.identifier.citedreference | Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. Desensitization: overcoming the immunologic barriers to transplantation. J Immunol Res. 2017; 2017: 6804678. https://doi.org/10.1155/2017/6804678 | |
dc.identifier.citedreference | Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid‐organ transplantation. Transplantation. 2018; 102 ( 6 ): 900 ‐ 931. https://doi.org/10.1097/TP.0000000000002191 | |
dc.identifier.citedreference | Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients ‐guidelines of the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019; 33 ( 9 ): e13512. https://doi.org/10.1111/ctr.13512 | |
dc.identifier.citedreference | Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence‐based practice guideline. Transfus Med Rev. 2010; 24 ( Suppl 1 ): S7 ‐ S27. | |
dc.identifier.citedreference | Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ. The treatment of antibody‐mediated rejection in kidney transplantation: an updated systematic review and meta‐analysis. Transplantation. 2018; 102 ( 4 ): 557 ‐ 568. | |
dc.identifier.citedreference | Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006; 26 ( 6 ): 813 ‐ 827. https://doi.org/10.1592/phco.26.6.813. PMID: 16716135 | |
dc.identifier.citedreference | Rocchio MA, Schurr JW, Hussey AP, Szumita PM. Intravenous immune globulin stewardship program at a tertiary academic medical center. Ann Pharmacother. 2017; 51 ( 2 ): 135 ‐ 139. | |
dc.identifier.citedreference | Figgins BS, Aitken SL, Whited LK. Optimization of intravenous immune globulin use at a comprehensive cancer center. Am J Health Syst Pharm. 2019; 76 ( Supplement_4 ): S102 ‐ S106. https://doi.org/10.1093/ajhp/zxz233. PMID: 31621877 | |
dc.identifier.citedreference | Krisl JC, Fortier CR, Taber DJ. Disruptions in the supply of medications used in transplantation: implications and management strategies for the transplant clinician. Am J Transplant. 2013; 13 ( 1 ): 20 ‐ 30. https://doi.org/10.1111/j.1600‐6143.2012.04308.x | |
dc.identifier.citedreference | Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV‐hyperimmuneglobulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta‐analysis. Clin Transplant. 2008; 22 ( 1 ): 89 ‐ 97. | |
dc.identifier.citedreference | Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2007; 2: CD005129. | |
dc.identifier.citedreference | Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations–a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med. 2002; 12 ( 2 ): 133 ‐ 139. | |
dc.identifier.citedreference | Miescher SM, Huber TM, Kühne M, et al. In vitro evaluation of cytomegalovirus‐specific hyperimmune globulins vs. standard intravenous immunoglobulins. Vox Sang. 2015; 109 ( 1 ): 71 ‐ 78. | |
dc.identifier.citedreference | Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation. 2011; 92 ( 3 ): 267 ‐ 270. | |
dc.identifier.citedreference | Shibaguchi H, Yamamoto T, Kuroki M, Futagami K. Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations. Yakugaku Zasshi. 2010; 130 ( 7 ): 977 ‐ 982. | |
dc.identifier.citedreference | Rituxan (rituximab). Package Insert. South San Francisco, CA: Genetech Inc. 2020. | |
dc.identifier.citedreference | Green H, Nesher E, Aizner S, et al. Long‐term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients. Clin Transplant. 2019; 33 ( 6 ): e13562. | |
dc.identifier.citedreference | Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti‐CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005; 45 ( 7 ): 792 ‐ 801. https://doi.org/10.1177/0091270005277075. PMID: 15951469 | |
dc.identifier.citedreference | Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004; 4 ( 6 ): 996 ‐ 1001. | |
dc.identifier.citedreference | Mulley WR, Hudson FJ, Tait BD, et al. A single low‐fixed dose of rituximab to salvage renal transplants from refractory antibody‐mediated rejection. Transplantation. 2009; 87 ( 2 ): 286 ‐ 289. | |
dc.identifier.citedreference | Cohen S, Emery P, Greenwald M, et al. A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol. 2016; 82 ( 1 ): 129 ‐ 138. | |
dc.identifier.citedreference | Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018; 7 ( 4 ): 3. | |
dc.identifier.citedreference | https://www1.magellanrx.com/documents/2019/03/medical‐pharmacy‐trend‐report_2018.pdf/. Accessed 9/6/2020 | |
dc.identifier.citedreference | Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to rituximab in an outpatient infusion center: a 5‐year review. J Allergy Clin Immunol Pract. 2017; 5 ( 1 ): 107 ‐ 113.e1. https://doi.org/10.1016/j.jaip.2016.06.022. Epub 2016 Aug 3. PMID: 27497683 | |
dc.identifier.citedreference | Keshvani N, Hon M, Gupta A, et al. Reducing hospitalizations: institution of outpatient infusional EPOCH‐Based chemotherapy at a safety net hospital. J Oncol Pract. 2019; 15 ( 8 ): e644 ‐ e651. https://doi.org/10.1200/JOP.18.00738. Epub 2019 Jun 17 PMID: 31206340 | |
dc.identifier.citedreference | Jorgenson MR, Descourouez JL, Brady BL, et al. Alternatives to immediate release tacrolimus in solid organ transplant recipients: When the gold standard is in short supply. Clin Transplant. 2020; 34 ( 7 ): e13903. https://doi.org/10.1111/ctr.13903. Epub 2020 May 29. PMID: 32400907 | |
dc.identifier.citedreference | Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011; 364 ( 20 ): 1909 ‐ 1919. | |
dc.identifier.citedreference | Pinson CW, Feurer ID, Payne JL, Wise PE, Shockley S, Speroff T. Health‐related quality of life after different types of solid organ transplantation. Ann Surg. 2000; 232 ( 4 ): 597 ‐ 607. https://doi.org/10.1097/00000658‐200010000‐00015 | |
dc.identifier.citedreference | Axelrod DA, Schnitzler MA, Xiao H, et al. An economic assessment of contemporary kidney transplant practice. Am J Transplant. 2018; 18 ( 5 ): 1168 ‐ 1176. https://doi.org/10.1111/ajt.14702 | |
dc.identifier.citedreference | James A, Mannon RB. The cost of transplant immunosuppressant therapy: is this sustainable? Curr Transplant Rep. 2015; 2 ( 2 ): 113 ‐ 121. https://doi.org/10.1007/s40472‐015‐0052‐y | |
dc.identifier.citedreference | Gharibi Z, Ayvaci MUS, Hahsler M, Giacoma T, Gaston RS, Tanriover B. Cost‐effectiveness of antibody‐based induction therapy in deceased donor kidney transplantation in the United States. Transplantation. 2017; 101 ( 6 ): 1234 ‐ 1241. https://doi.org/10.1097/TP.0000000000001310 | |
dc.identifier.citedreference | Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Syst Rev. 2010;( 1 ): CD003897. https://doi.org/10.1002/14651858.CD003897.pub3 | |
dc.identifier.citedreference | Simulect. Package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. | |
dc.identifier.citedreference | Lorber MI, Fastenau J, Wilson D, DiCesare J, Hall ML. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin Transplant. 2000; 14 ( 5 ): 479 ‐ 485. https://doi.org/10.1034/j.1399‐0012.2000.140506.x. PMID: 11048993 | |
dc.identifier.citedreference | Guerra G, Ciancio G, Gaynor JJ, et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol. 2011; 9: 1758 ‐ 1768. | |
dc.identifier.citedreference | Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin‐2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995; 60: 748 ‐ 756 4. | |
dc.identifier.citedreference | Kovarik JM, Rawlings E, Sweny P, et al. Pharmacokinetics and immunodynamics of chimeric IL‐2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transpl Int. 1996; 9 ( Suppl 1 ): S32 ‐ S33. 5. | |
dc.identifier.citedreference | Mehra M, Zucker MJ, Wagoner L. Multicenter, prospective, randomized, double‐blind trial of basiliximab in heart transplantation. J Heart Lung Transplant. 2005; 24: 1297 ‐ 1304. | |
dc.identifier.citedreference | Cunningham KC, Hager DR, Fischer J, et al. Single‐dose basiliximab induction in low‐risk renal transplant recipients. Pharmacotherapy. 2016; 36 ( 7 ): 823 ‐ 829. https://doi.org/10.1002/phar.1774 | |
dc.identifier.citedreference | Baquero A, Pérez J, Rizik N, et al. Basiliximab: a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation. Transplant Proc. 2006; 38 ( 3 ): 909 ‐ 910. https://doi.org/10.1016/j.transproceed.2006.02.052 | |
dc.identifier.citedreference | Richards KR, Hager D, Muth B, Astor BC, Kaufman D, Djamali A. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. Transplantation. 2014; 97 ( 10 ): 986 ‐ 991. https://doi.org/10.1097/TP.0000000000000149 | |
dc.identifier.citedreference | Kittipibul V, Tantrachoti P, Ongcharit P. Low‐dose basiliximab induction therapy in heart transplantation. Clin Transpl. 2017; 31 ( 12 ): e13132. | |
dc.identifier.citedreference | McAdams‐DeMarco MA, King EA, Luo X, et al. Frailty, length of stay, and mortality in kidney transplant recipients: a national registry and prospective cohort study. Ann Surg. 2017; 266 ( 6 ): 1084 ‐ 1090. https://doi.org/10.1097/SLA.0000000000002025 | |
dc.identifier.citedreference | Alloway RR, Woodle ES, Abramowicz D, et al. Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation. Am J Transpl. 2019; 19: 2252 ‐ 2261. | |
dc.identifier.citedreference | Gurk‐Turner C, Airee R, Philosophe B, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation. 2008; 85 ( 10 ): 1425 ‐ 1430. https://doi.org/10.1097/TP.0b013e31816dd596. PMID: 18497682 | |
dc.identifier.citedreference | Singh N, Rossi AP, Savic M, Rubocki RJ, Parker MG, Vella JP. Tailored rabbit antithymocyte globulin induction dosing for kidney transplantation. Transpl Direct. 2018; 4 e: 343. | |
dc.identifier.citedreference | Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short‐course for induction in kidney transplantation. Transplant Int. 2006; 19: 629 ‐ 635. | |
dc.identifier.citedreference | Klem P, Cooper JE, Weiss AS, et al. Reduced dose rabbit anti‐thymocyte globulin induction for prevention of acute rejection in high‐risk kidney transplant recipients. Transplantation. 2009; 88: 891 ‐ 896. | |
dc.identifier.citedreference | Machado FP, Vicari AR, Spuldaro F, Castro Filho JBS, Manfro RC. Polyclonal anti T‐lymphocyte antibody therapy monitoring in kidney transplant recipients: comparison of CD3+ T cell and total lymphocyte counts. Einstein (Sao Paulo). 2018; 16 ( 4 ): eAO4278. https://doi.org/10.31744/einstein_journal/2018AO4278. PMID: 30517367; PMCID: PMC6276809 | |
dc.identifier.citedreference | Varga AN, Johnson D, Sawinski DL, et al. Safety and feasibility of outpatient rabbit antithymocyte globulin induction therapy administration in kidney transplant recipients. Pharmacotherapy. 2018; 38: 620 ‐ 627. | |
dc.identifier.citedreference | Peddi VR, Bryant M, Roy‐Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney‐pancreas transplant recipients. Transplantation. 2002; 73 ( 9 ): 1514 ‐ 1518. | |
dc.identifier.citedreference | Djamali A, Turc‐Baron C, Portales P, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T‐cell monitoring. Transplantation. 2000; 69 ( 5 ): 799 ‐ 805. | |
dc.identifier.citedreference | Uber WE, Uber LA, VanBakel AB, et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc. 2004; 36 ( 10 ): 3245 ‐ 3249. | |
dc.identifier.citedreference | Thymoglobulin [Package Insert]. Cambridge, MA, Genzyme Corporation, 2020. | |
dc.identifier.citedreference | Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti‐thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996; 45 ( 1 ): 29 ‐ 32. | |
dc.identifier.citedreference | Vacha M, Gommer J, Rege A, Sanoff S, Sudan D, Harris M. Effects of ideal versus total body weight dosage of rabbit antithymocyte globulin on outcomes of kidney transplant patients with high immunologic risk. Exp Clin Transpl. 2016; 5: 511 ‐ 517. | |
dc.identifier.citedreference | Curran SP, Famure O, Li Y, Kim SJ. Increased recipient body mass index is associated with acute rejection and other adverse outcomes after kidney transplantation. Transplantation. 2014; 97 ( 1 ): 64 ‐ 70. | |
dc.identifier.citedreference | Miller R, Meadows H, Strout S, et al. Safety, Efficacy, and Cost Saving Potential of Various Weight‐Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 ( suppl 3 ). https://atcmeetingabstracts.com/abstract/safety‐efficacy‐and‐cost‐saving‐potential‐of‐various‐weight‐based‐dosing‐for‐thymoglobulin‐induction‐therapy‐in‐kidney‐transplant‐recipients/. Accessed November 30, 2020 | |
dc.identifier.citedreference | Tsapepas D, Mohan S, Tanriover B, et al. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal. Transpl J. 2012; 94 ( 4 ): 325 ‐ 330. https://doi.org/10.1097/tp.0b013e318257ad1a | |
dc.identifier.citedreference | Pennington C, Tischer S, Lee E, Lee S, Sindelar J, Park J. Evaluation of a weight‐based rabbit anti‐thymocyte globulin induction dosing regimen for kidney transplant recipients. Pharmacother J Human Pharmacol Drug Ther. 2015; 35 ( 8 ): 748 ‐ 754. https://doi.org/10.1002/phar.1624 | |
dc.identifier.citedreference | Trofe‐Clark J, Reese P, Patel H, et al. Efficacy and safety of extended‐duration inpatient‐to‐outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients. Transpl J. 2012; 94 ( 5 ): 506 ‐ 512. https://doi.org/10.1097/tp.0b013e31825c58c0 | |
dc.identifier.citedreference | Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 2002; 73 ( 3 ): 473 ‐ 475. https://doi.org/10.1097/00007890‐200202150‐00025. PMID: 11884948 | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.